Communicate with Supplier? Supplier
Kelly Ms. Kelly
What can I do for you?
Chat Now
Chat Now Contact Supplier
  • +86-0635-6175299
  • Company Details

 Shandong Haohong Biotechnology Co., Ltd.

  • All
  • Title
  • All
  • Title
HomeProductsAnti-cancer Drug

Anti-cancer Drug

Product categories of Anti-cancer Drug, we are specialized manufacturers from China, Anticancer Drug Classification, Anticancer Drug List suppliers/factory, wholesale high-quality products of Cabozantinib Intermediates R & D and manufacturing, we have the perfect after-sales service and technical support. Look forward to your cooperation!

China leading manufacturers and suppliers of Anticancer Drug , and we are specialized in Cabozantinib Intermediates, Alectinib Intermediates, Ceritinib Intermediates, Larotrectinib Intermediates, Ponatinib Intermediates, Ruxolitinib Intermediates,Anticancer Drug Development, etc.If you want to buy Anti-cancer Drugs,please contact us.

Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc.

Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011. Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers.

Cabozantinib will be distributed in Europe by the French pharmaceutical company Ipsen after a collaboration was reached with Exelixis in March of 2016.

Alectinib is a highly selective and potent anaplastic lymphoma kinase (ALK) inhibitor capable of blocking the resistant gatekeeper mutant, which results in reduced cell growth. CH5424802 have been clinically evaluated for the treatment of patients with ALK-driven tumors.

Ceritinib (INN, trade name Zykadia) is a drug for the treatment of a specific type of lung cancer. It is an anaplastic lymphoma kinase (ALK) inhibitor. It was developed by Novartis. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients that failed treatment with crizotinib. It is a more effective, but more toxic, alternative to traditional platinum-based chemotherapies. Ceritinib was found at physiological concentrations to inhibit ALK, insulin-like growth factor 1 receptor (IGF-1R), and ROS1.

Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).

Ponatinib (trade name Iclusig, previously AP24534) is an oral drug developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). It is a multi-targeted tyrosine-kinase inhibitor. Some forms of CML, those that have the T315I mutation, are resistant to current therapies such as imatinib. Ponatinib has been designed to be effective against these types of tumors.

Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.




About Us